PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 13, 2026RSC Advances2 citationsOpen Access

Novel donor-π-acceptor benzimidazole-based chromophores: synthesis, antitumor assessment, and pharmacokinetics

SASalhah D. Al-QahtaniGAGhadah M. Al-SenaniKEKhaled M. Elattar

Key Points

  • The aim is to synthesize benzimidazole-based chromophores and evaluate their antitumor effects and pharmacokinetics.
  • Synthesis of benzimidazole hybrids
  • Assessment of cytotoxicity in HepG2, PC3, MCF-7, and WI-38 cells
  • VEGFR-2 inhibition and molecular docking studies
  • Benzimidazole hybrids exhibited selective cytotoxicity against HepG2, PC3, and MCF-7 cancer cells.
  • Low toxicity was observed in WI-38 cells.
  • Strong binding to VEGFR-2 was confirmed, indicating potential for anticancer and anti-angiogenic therapies.

Abstract

Benzimidazole hybrids showed selective cytotoxicity against HepG2, PC3, and MCF-7 cancer cells with low toxicity to WI-38 cells. VEGFR-2 inhibition and docking confirmed strong binding, indicating promising anticancer and anti-angiogenic activity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Al-Qahtani et al. (2026) studied this question.

synapsesocial.com/papers/69b3acd302a1e69014cced8chttps://doi.org/10.1039/d6ra00254d
Ask AI
Helpful
Bookmark
Share
View Full Paper